PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: An international multicenter study

J Ferdinandus, WP Fendler, A Farolfi… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The European Association of Urology (EAU) prostate cancer guidelines panel recommends
risk groups for biochemical recurrence (BCR) of prostate cancer to identify men at high risk …

Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study …

JJ Cerci, S Fanti, EE Lobato… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Biochemical recurrence (BCR) is a clinical challenge in prostate cancer (PCa) patients, as
recurrence localization guides subsequent therapies. The use of PET with prostate-specific …

The European Association of Urology biochemical recurrence risk groups predict findings on PSMA PET in patients with biochemically recurrent prostate cancer after …

L Dong, Y Su, Y Zhu, MC Markowski… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Our purpose was to evaluate the association of a new biochemical recurrence (BCR) risk
stratification system with PSMA-targeted PET/CT findings. Methods: Two prospective studies …

PSMA PET for Detection of Recurrence

H Duan, A Iagaru - Seminars in Nuclear Medicine, 2023 - Elsevier
Prostate cancer (PC) is a significant health concern worldwide, with high incidence and
mortality rates. Early and accurate detection and localization of recurrent disease at …

Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence—a narrative review of the …

Ö Ekmekcioglu, M Busstra, ND Klass… - Journal of Nuclear …, 2019 - Soc Nuclear Med
68Ga-and 18F-labeled prostate-specific membrane antigen (PSMA) molecules have created
new opportunities for the unmet diagnostic needs in prostate cancer. The purpose of this …

The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology …

A Joshi, MJ Roberts, M Perera, E Williams… - Clinical & Experimental …, 2020 - Springer
Prospective evidence for the clinical role and efficacy of prostate specific membrane antigen
(PSMA) positron emission tomography (PET)/magnetic resonance imaging (MRI) combining …

[HTML][HTML] 68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective …

J Martinez, K Subramanian, D Margolis, E O'Dwyer… - Translational …, 2022 - Elsevier
Background The primary objective was to compare the overall diagnostic performance,
presented as detection rate of 68 Ga-PSMA-HBED-CC positron emission …

[HTML][HTML] PSMA PET-CT imaging predicts treatment progression in men with biochemically recurrent prostate cancer—a prospective study of men with 3 year follow up

S Ong, C Pascoe, BD Kelly, Z Ballok, D Webb, D Bolton… - Cancers, 2022 - mdpi.com
Simple Summary Prostate-specific membrane antigen (PSMA) positron emission
tomography-computed tomography (PET-CT) is an essential imaging tool that is used to …

Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent …

L Bukavina, AN Luckenbaugh, MS Hofman, T Hope… - European Urology, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA) is a promising molecular target for
prostate cancer (PCa) that has allowed the development of a novel diagnostic approach to …

Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 …

L Djaïleb, WR Armstrong, D Thompson, A Gafita… - European Urology, 2023 - Elsevier
Background In the initial staging of patients with high-risk prostate cancer (PCa), prostate-
specific membrane antigen positron emission tomography (PSMA-PET) has been …